Proteins that bind IL-1 and IL-1 are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1 and IL-1 in cells, tissues, samples, and compositions.

Disclosed herein are formulations, substrates, and arrays. Also disclosed herein are methods for manufacturing and using the formulations, substrates, and arrays. Also disclosed are methods for identifying peptide sequences useful for diagnosis and treatment of disorders, and methods for using the peptide sequences for diagnosis and treatment of disorders, e.g., celiac disorder. In certain embodiments, substrates and arrays comprise a porous layer for synthesis and attachment of polymers or biomolecules.

The present invention relates to a novel antibody against HERV-K envelope that targets a conserved region not affected by glycosylation or by native conformation, and its use in diagnostics and/or in therapy.

The present invention relates to a stable method for introducing at least one inducible cassette into a cell, and permitting controllable transcription from within that inducible cassette. The method may be used for any cell type, from any eukaryotic organism, but has a particular application in the introduction of inducible cassettes into pluripotent stem cells, such as animal or human pluripotent stem cells (hPSCs). The inducible cassette is controllably inserted in such a way to ensure that the genetic material it contains is not silenced or subject to negative influences from the insertion site, and transcription of the genetic material is controlled.

Chronic Kidney Disease (CKD) is characterized by the progressive loss of renal function which eventually leads to End Stage Renal Disease (ESRD). CKD affects roughly 30 million Americans, costs billions of dollars in healthcare spending annually, and leaves thousands of patients reliant on burdensome dialysis treatments while waiting for a transplant. Fortunately, CKD may be controllable if diagnosed early in the disease progression. RAMETRIX? is a novel public health screening technology for early diagnosis and detection of CKD. This technology uses Raman spectroscopy and chemometrics to analyze the molecular composition of urine and other biological fluids. RAMETRIX? is a fast, non-invasive, accurate, and inexpensive diagnostic tool that can revolutionize the way healthcare providers detect and treat CKD. The RAMETRIX? AutoScanner is a system enabling more efficient sample processing in large-scale settings such as hospitals and medical laboratories.

The present invention relates to a smart defecation plate including a companion animal medical examination kit. More specifically, the smart defecation plate includes: a body the center of which is formed in a concave shape; an upper plate which is coupled to the top of the body, and in which defecation holes are formed in a grid pattern; a pad part which includes a waterproof pad and absorption pads attached to the waterproof pad and configured to absorb a fluid entering through the defecation holes and which is disposed between the body and the upper plate; and a medical examination kit which is disposed on the top of the pad part. According to the present invention, the medical examination kit is provided on the top of the pad part, and thus the health state of a companion animal may be diagnosed through an introduced fluid.

The present invention relates to a stable method for introducing at least one inducible cassette into a cell, and permitting controllable transcription from within that inducible cassette. The method may be used for any cell type, from any eukaryotic organism, but has a particular application in the introduction of inducible cassettes into pluripotent stem cells, such as animal or human pluripotent stem cells (hPSCs). The inducible cassette is controllably inserted in such a way to ensure that the genetic material it contains is not silenced or subject to negative influences from the insertion site, and transcription of the genetic material is controlled.

A system and method for photo-thermal imaging of a lateral flow immunoassay (LFA) device are provided. The system includes an intensity modulated heat source directed at a surface of the LFA device to selectively excite chromophore particles of interest and a thermal capture device configured to capture thermal waves emitted from the surface of the LFA device as a radiometric signal. A computing device, in communication with the thermal capture device, receives the radiometric signal and executes lock-in demodulation to detect surface or subsurface inhomogeneities of the LFA device.

The invention principally relates to a method of detecting a disease agent in blood, comprising: (i) creating a sample infra-red spectrum representative of the blood, with one or more spectral components, each having a wavenumber and absorbance value; (ii) providing a reference database of spectral models, each model having one or more database spectral components of a wavenumber and an absorbance value, wherein the database spectral components identify disease agents; (iii) determining whether one or more database spectral components corresponds to one or more sample spectral components, and (iv) compiling a list of corresponding database components identified.

Methods are described herein for small molecule biochemical profiling of an individual subject for diagnosis of a disease or disorder, facilitating diagnosis of a disease or disorder, and/or identifying an increased risk of developing a disease or disorder in the individual subject. Aberrant levels of small molecules present in a sample from an individual subject are identified and diagnostic information relevant to the individual subject is obtained based on the identified aberrant levels. The obtained diagnostic information includes one or more of an identification of at least one biochemical pathway associated with the identified subset of the small molecules having aberrant levels, an identification at least one disease or disorder associated with the identified subset of the small molecules having aberrant levels, and an identification of at least one recommended follow up test associated with the identified subset of the small molecules having aberrant levels.